SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): October 20,
2022
IONIS PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
Delaware
(State or Other Jurisdiction of Incorporation)
000-19125
|
|
33-0336973
|
(Commission File No.)
|
|
(IRS Employer Identification No.)
|
2855 Gazelle Court
Carlsbad, CA 92010
(Address of Principal Executive Offices and Zip Code)
Registrant’s telephone number, including area code: (760)
931-9200
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act
(17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the
Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the
Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
|
|
Trading symbol
|
|
Name of each exchange on which registered
|
Common Stock, $.001 Par Value
|
|
“IONS”
|
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933
(Section 230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (Section 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
☐
Item 1.01 |
Entry into a Material Definitive Agreement.
|
Purchase and Sale Agreements and Lease Agreements
On October 20, 2022, Ionis Gazelle, LLC (“Ionis
Gazelle”), a wholly owned subsidiary of Ionis
Pharmaceuticals, Inc. (“Ionis”),
entered into a purchase and sale agreement (the “Campus
Purchase Agreement”) with 2850 2855 & 2859 Gazelle Owner
(DE) LLC (the “Campus
Purchaser”), a subsidiary of Oxford Properties Group,
pursuant to which Ionis Gazelle agreed to sell certain real estate
located at 2850, 2855 and 2859 Gazelle Court, Carlsbad, California
(the “Existing
Campus”) to the Campus Purchaser for a purchase price of
$258.4 million (the “Campus
Sale-Leaseback Transaction”), plus $5.0 million held in
escrow (the “Additional
Purchase Price”), subject to terms and conditions contained
in the Campus Purchase Agreement. The closing of the Campus
Sale-Leaseback Transaction occurred concurrently with the parties’
execution of the Campus Purchase Agreement. On October 20, 2022,
Ionis concurrently entered into a purchase and sale agreement (the
“BTS
Purchase Agreement”) with Oxford I Asset Management USA Inc.
(the “BTS
Purchaser”), also a subsidiary of Oxford Properties Group,
pursuant to which Ionis agreed to sell certain real estate
consisting of vacant land located near the Existing Campus,
comprising Lots 21 and 22, Carlsbad Oaks North Business Park,
Carlsbad, California (the “BTS
Property”) to the BTS Purchaser for a purchase price of
$33.0 million (the “BTS
Sale-Leaseback Transaction”), subject to terms and
conditions contained in the BTS Purchase Agreement. The closing of
the BTS Sale-Leaseback Transaction will occur after, and is
contingent upon, Ionis obtaining entitlements necessary to
construct certain office and laboratory improvements on the BTS
Property (the “Improvements”).
If closing of the BTS Sale-Leaseback Transaction occurs, the
purchase price for the Existing Campus will be deemed to have
increased by $5.0 million, to $263.4 million in the aggregate, and
the Additional Purchase Price will be released from escrow to
Ionis.
Upon the closing of the Campus Sale-Leaseback Transaction, Ionis
and the Campus Purchaser concurrently entered into a lease
agreement (the “Campus
Lease”), pursuant to which Ionis leases the Existing Campus
from the Campus Purchaser for an initial term of 180 months (which
term will automatically be extended to be co-terminus with the term
of the BTS Lease (defined below), if closing of the BTS
Sale-Leaseback Transaction occurs), with two renewal options of
five years each. The total annual base rent under the Campus Lease
is currently $15,542,037 per year, and will increase annually by
the Consumer Price Index, subject to a floor of 2.5% and ceiling of
5.5%. Ionis will also be responsible for payment of all operating
expenses, property taxes and insurance for the Existing Campus.
Pursuant to the terms of the Campus Lease, Ionis has a right of
first offer to purchase the Existing Campus should the Campus
Purchaser intend to sell the Existing Campus to a third
party.
If closing of the BTS Sale-Leaseback Transaction occurs, Ionis and
the BTS Purchaser will enter into a lease agreement (the
“BTS
Lease”), pursuant to which Ionis will lease the
to-be-constructed Improvements on the BTS Property from the BTS
Purchaser for an initial term of 180 months, with two renewal
options of five years each. Upon entering into the BTS Lease, the
BTS Purchaser will, at its cost, construct the shell and core of
the Improvements, and Ionis will, at its cost (but subject to
reimbursement from a tenant improvement allowance from the BTS
Purchaser), complete the tenant improvements for the Improvements.
The term of the BTS Lease will commence on the date that is the
earlier of (i) ten months following delivery of the Improvements to
Ionis for commencement of construction of the tenant improvements,
and (ii) the date Ionis begins operating in the premises for
business purposes. The total annual base rent under the BTS Lease
for the first year of the term will equal 6.35% multiplied by the
costs incurred by the BTS Purchaser to acquire, design, construct,
finance, and otherwise develop the shell and core of the
Improvements, including, among other things, the tenant improvement
allowance. Such base rent will increase annually by the Consumer
Price Index, subject to a floor of 2.5% and ceiling of 5.5%. Ionis
will also be responsible for payment of all operating expenses,
property taxes and insurance for the BTS Property and Improvements.
Pursuant to the terms of the BTS Lease, Ionis has a right of first
offer to purchase the BTS Property and Improvements should the BTS
Purchaser intend to sell the BTS Property and Improvements to a
third party.
The foregoing description of the material terms of (i) the Campus
Purchase Agreement is qualified in its entirety by reference to the
full text of the Campus Purchase Agreement, (ii) the BTS Purchase
Agreement is qualified in its entirety by reference to the full
text of the BTS Purchase Agreement, and (iii) the Campus Lease is
qualified in its entirety by reference to the full text of the
Campus Lease, a copy of each of which will be filed as an exhibit
to the Company’s Annual Report on Form 10-K for the quarter and
year ended December 31, 2022.
Defeasance Agreement
On October 20, 2022, Ionis Gazelle, as “Original
Borrower,”
entered into a Defeasance Pledge and Security Agreement (the
“Defeasance
Agreement”)
with Wells Fargo Bank, National Association, as Trustee for the Benefit of the Registered
Holders of UBS Commercial Mortgage Trust 2017-C3, Commercial
Mortgage Pass-Through Certificates, Series 2017-C3, as secured
party (Trustee or its successors and assigns, “Lender”),
and, for the sole purpose of agreeing to the provisions of Sections
6(a)(viii), 7, 8, 9(b), 12, 14, 15, 16, 22, 25 and 26 of the
Defeasance Agreement, U.S. Bank Trust Company, National
Association, a national banking association, as Securities
Intermediary and Custodian (together with its successors and
assigns, “Intermediary”).
UBS AG, by and through its branch office at 1285 Avenue of the
Americas, New York, New York (“Original
Lender”), made a loan (the “Mortgage
Loan”) to Original Borrower in the original principal amount
of $51.35 million, pursuant
to a Loan Agreement dated
July 18, 2017 between Ionis Gazelle and UBS AG (the
“Loan
Agreement”),
and evidenced by (1) a Promissory Note A-1 dated July 18,
2017 in the original principal amount of $36.35 million (the
“Note
A-1”), (2) a Promissory Note A-2 dated July 18, 2017 in the
original principal amount of $5.0 million (the “Note
A-2”), and (3) a Promissory Note A-3 dated July 18, 2017 in
the original principal amount of $10.0 million (Note A-1, Note A-2
and Note A‑3 are, individually and collectively, the “Note”
or the “Notes”).
The Mortgage Loan and the Notes were secured by, among other
things, a Deed of Trust and Security Agreement dated July 18, 2017
from Original Borrower to and for the benefit of Original Lender
(the “Security
Instrument”), which granted to Original Lender, among other
things, a lien on the real and personal property described in the
Security Instrument (the “Mortgaged
Property”). The Mortgage Loan was further evidenced or
secured by various other documents, including guaranties, executed
by Original Borrower and others in favor of Original Lender
(together with the Notes, the Loan Agreement and the Security
Instrument, the “Mortgage
Loan Documents”). Original Lender assigned all of its
right, title and interest in the Mortgage Loan and the Mortgage
Loan Documents, by one or more assignments, to Lender in connection
with the issuance of UBS Commercial Mortgage Trust 2017-C3,
Commercial Mortgage Pass-Through Certificates, Series 2017-C3.
Midland Loan Services, a division of PNC Bank, National Association
(“Servicer”),
is the Master Servicer under the Pooling and Servicing Agreement
dated as of August 1, 2017.
Pursuant to the Mortgage Loan Documents, Original Borrower directed
Lender to release the Mortgaged Property and all escrows and
reserves from the liens and security interests of the Security
Instrument and to release any other collateral or security
previously given by Original Borrower as security for the Mortgage
Loan upon Original Borrower’s defeasance of the Mortgage Loan (the
“Defeasance”).
Original Borrower is the legal and beneficial owner of the
securities listed in Exhibit A to the Defeasance Agreement.
Pursuant to the Mortgage Loan Documents, one of the conditions
precedent to Lender’s obligation to release the lien of the
Security Instrument on the Mortgaged Property is that Original
Borrower grant a security interest in the Pledged Collateral, as
defined in the Defeasance Agreement, to Lender to secure the
payment and performance in full when due of all amounts payable
under the Mortgage Loan Documents.
Following the execution of the Defeasance Agreement, Lender,
Servicer, Original Borrower, DHC UBSCM 17 C3 Successor Borrower-R,
LLC, a Delaware limited liability company (“Successor
Borrower”), and Intermediary entered into the Defeasance
Assignment, Assumption and Release Agreement, dated October 20,
2022 (the “Defeasance
Assignment Agreement”), pursuant to which, among other
things, Original Borrower transferred the Pledged Collateral, as
defined in the Defeasance Agreement, to Successor Borrower and, to
the extent set forth in the Defeasance Agreement and related
documents, Successor Borrower assumed the rights and obligations of
Original Borrower under (i) the Notes, (ii) the Defeasance
Agreement, and (iii) the Defeasance Account Agreement dated as of
October 20, 2022 among Original Borrower, Lender, Servicer,
Intermediary and U.S. Bank National Association as account bank
(the “Defeasance
Account Agreement”).
The foregoing description of the material terms of (i) the
Defeasance Agreement is qualified in its entirety by reference to
the full text of the Defeasance Agreement, (ii) the Defeasance
Assignment Agreement is qualified in its entirety by reference to
the full text of the Defeasance Assignment Agreement, and (iii) the
Defeasance Account Agreement is qualified in its entirety by
reference to the full text of the Defeasance Account Agreement, a
copy of each of which will be filed as an exhibit to the Company’s
Annual Report on Form 10-K for the quarter and year ended December
31, 2022.
Item 2.01. |
Completion of Acquisition or Disposition of Assets.
|
The information set forth in Item 1.01 is incorporated herein by
reference.
Item 2.03. |
Creation of a Direct Financial Obligation or an Obligation under an
Off-Balance Sheet Arrangement of a Registrant.
|
The information set forth in Item 1.01 is incorporated herein by
reference.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of
1934, as amended, the registrant has duly caused this report to be
signed on its behalf by the undersigned, thereunto duly
authorized.
|
Ionis Pharmaceuticals, Inc.
|
|
|
|
Dated: October 24, 2022
|
By:
|
/s/ Patrick R.
O’Neil
|
|
|
Patrick R. O’Neil
|
|
|
Executive Vice President, Chief Legal Officer and General
Counsel
|